XML 43 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Asset Impairment, Restructuring, and Other Special Charges
 12 Months Ended
Dec. 31, 2021
Restructuring and Related Activities [Abstract]  
Asset Impairment, Restructuring, And Other Special Charges Asset Impairment, Restructuring, and Other Special Charges
The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated statements of operations are described below:
202120202019
Severance$13.0 $151.2 $77.8 
Asset impairment (gain) and other special charges303.1 (20.0)497.8 
Total asset impairment, restructuring, and other special charges$316.1 $131.2 $575.6 
Severance costs recognized during the years ended December 31, 2020 and 2019 were incurred as a result of actions taken worldwide to reduce our cost structure.
During the year ended December 31, 2021, we recognized $128.0 million of intangible asset impairment as a result of the decision by Bayer AG to discontinue the development of a Phase I molecule related to a contract-based intangible asset from our acquisition of Loxo. Additionally, we recognized $108.1 million of intangible asset impairment from the sale of the rights to Qbrexza, as well as acquisition and integration costs associated with the acquisition of Prevail.
Asset impairment and other special charges recognized during the year ended December 31, 2019 resulted primarily from $400.7 million of other special charges related to the acquisition of Loxo, substantially all of which is associated with the accelerated vesting of Loxo employee equity awards.